(Adnkronos) - Delusione e sorpresa per quanto previsto in manovra per il settore farmaceutico. È questo il commento di Farmindustria, l’Associazione delle imprese farmaceutiche, che, nonostante l’apprezzamento per quanto previsto per il fondo dei farmaci innovativi, è delusa dall'assenza di un innalzamento del tetto della spesa farmaceutica e dall’articolo 57, che dovrebbe ridurre le quote di spettanza, e dunque i margini, delle aziende farmaceutiche a favore della distribuzione.
Category
🗞
NewsTranscript
00:00After the meeting with the competent ministers Giorgetti and Schillaci, the president of
00:09Pharmindustria, Marcello Cattani, explains that despite the appreciation for what is
00:13expected for the Fund of Innovative Pharmaceuticals, the association is disappointed by the absence
00:18of an increase in the roof of pharmaceutical spending and Article 57, which should reduce
00:24the expected rates and therefore the margins of pharmaceutical companies in favor of distribution.
00:54For President Cattani, the pharmaceutical industry is a fundamental engine for competitiveness
01:01in Italy and Europe.
01:31As President Meloni said at the time of his elections, the country and Europe need an
01:38industrial strategy, above all that helps sectors that give the greatest competitiveness,
01:45such as the pharmaceutical industry, the number one sector in Italy on this, and Europe for
01:52the value of production, and therefore Europe is called to the bell of the last lap of
01:59the American elections, where there will be a further competitive push of the possible
02:06DAFs on the American front and therefore we must be quick to have a strategy for the
02:13sciences of life, where to protect the patent and where to invest in research and development
02:20and industrial production, but if the line of Europe is ideological against the patent
02:27of the pharmaceutical industry, then it is time now to reverse the pharmaceutical legislation
02:34that wanted to shorten the patent by lengthening it, we must lengthen it as the United States
02:41and China, and above all to support the industrial production of all drugs, even those that
02:47for a wrong economic ideology have been cut in recent years, and therefore the issue of
02:54patents must be solved with a strategy that brings back the production of active ingredients
02:59in Europe and that gives the right valuation, rapid access to all drugs, this is the way,
03:05but it needs a vision and a strategy that we strongly ask for.